The proteasome: structure, function, and role in the cell

被引:463
作者
Adams, J [1 ]
机构
[1] Millennium Pharmaceut Inc, Cambridge, MA 02139 USA
关键词
proteasome inhibition; regulatory protein; tumor; cancer;
D O I
10.1016/S0305-7372(03)00081-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The proteasome is a multisubunit enzyme complex that plays a central role in the regulation of proteins that control cell-cycle progression and apoptosis, and has therefore become an important target for anticancer therapy. Before a protein is degraded, it is first flagged for destruction by the ubiquitin conjugation system, which ultimately results in the attachment of a polyubiquitin chain on the target protein. The proteasome's 19S regulatory cap binds the polyubiquitin chain, denatures the protein, and feeds the protein into the proteasome's proteolytic core. The proteolytic core is composed of 2 inner beta rings and 2 outer alpha rings. The 2 beta rings each contain 3 proteolytic sites named for their trypsin-like, post-glutamyl peptide hydrolase-like (PGPH) (i.e., caspase-like), or chymotrypsin-like activity. Inhibition of the proteasome results in cell-cycle arrest and apoptosis. In in vitro and in vivo animal studies, inhibition of the proteasome via bortezomib (VELCADE; formerly, PS-341, LDP-341, and MLN341) had antitumor activity against numerous tumor types either alone or in combination with conventional chemotherapeutic agents; these results provided the rationale for a broad clinical trial program. Bortezomib is currently in phase III trials for myeloma and is.-in early clinical development for numerous other tumor types. (C) 2003 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:3 / 9
页数:7
相关论文
共 47 条
[1]  
Adams J, 1999, CANCER RES, V59, P2615
[2]   Potent and selective inhibitors of the proteasome: Dipeptidyl boronic acids [J].
Adams, J ;
Behnke, M ;
Chen, SW ;
Cruickshank, AA ;
Dick, LR ;
Grenier, L ;
Klunder, JM ;
Ma, YT ;
Plamondon, L ;
Stein, RL .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (04) :333-338
[3]   Protease inhibitor-induced apoptosis:: accumulation of wt p53, p21WAF1/CIP1 and induction of apoptosis are independent markers of proteasome inhibition [J].
An, WG ;
Hwang, SG ;
Trepel, JB ;
Blagosklonny, MV .
LEUKEMIA, 2000, 14 (07) :1276-1283
[4]   Covalent modification of the active site threonine of proteasomal beta subunits and the Escherichia coli homolog HslV by a new class of inhibitors [J].
Bogyo, M ;
McMaster, JS ;
Gaczynska, M ;
Tortorella, D ;
Goldberg, AL ;
Ploegh, H .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (13) :6629-6634
[5]   Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome [J].
Bold, RJ ;
Virudachalam, S ;
McConkey, DJ .
JOURNAL OF SURGICAL RESEARCH, 2001, 100 (01) :11-17
[6]   The Rel/NF-κB family directly activates expression of the apoptosis inhibitor Bcl-xL [J].
Chen, CL ;
Edelstein, LC ;
Gélinas, C .
MOLECULAR AND CELLULAR BIOLOGY, 2000, 20 (08) :2687-2695
[7]   Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma [J].
Chiarle, R ;
Budel, LM ;
Skolnik, J ;
Frizzera, G ;
Chilosi, M ;
Corato, A ;
Pizzolo, G ;
Magidson, J ;
Montagnoli, A ;
Pagano, M ;
Maes, B ;
De Wolf-Peeters, C ;
Inghirami, G .
BLOOD, 2000, 95 (02) :619-626
[8]  
Cusack JC, 2001, CANCER RES, V61, P3535
[9]   The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-α-initiated apoptosis [J].
Delic, J ;
Masdehors, P ;
Ömura, S ;
Cosset, JM ;
Dumont, J ;
Binet, JL ;
Magdelénat, H .
BRITISH JOURNAL OF CANCER, 1998, 77 (07) :1103-1107
[10]   Mechanistic studies on the inactivation of the proteasome by lactacystin A central role for clasto-lactacystin beta-lactone [J].
Dick, LR ;
Cruikshank, AA ;
Grenier, L ;
Melandri, FD ;
Nunes, SL ;
Stein, RL .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (13) :7273-7276